Afamelanotide.
Afamelanotide is a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH), historically studied under the research name Melanotan I.
Afamelanotide is a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH), historically studied under the research name Melanotan I. Afamelanotide is fda-approved, and PepCue grades its published evidence A tier (88/100). Also known as Melanotan I · Scenesse. This is a research reference, not medical or dosing advice.
What it is
Afamelanotide is a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH), historically studied under the research name Melanotan I. It is formulated as a slow-release bioresorbable implant (Scenesse, Clinuvel) placed subcutaneously roughly every two months. Its approved use is not cosmetic tanning but photoprotection: increasing the amount of pain-free light exposure in adults with erythropoietic protoporphyria (EPP), a rare inherited condition causing severe phototoxic pain. It is one of the very few peptide analogs of alpha-MSH to complete formal Phase 3 development and gain regulatory approval. It is grouped under cosmetic here only because it acts on skin pigmentation pathways; clinically it is a photoprotective orphan drug.
How it works
Afamelanotide is an agonist at melanocortin-1 receptors (MC1R) on epidermal melanocytes. Activating MC1R stimulates production of eumelanin, the darker, more photoprotective form of melanin, independent of ultraviolet exposure. Increased eumelanin absorbs and scatters visible and UV light, reducing the free-radical and phototoxic response that causes pain in EPP, where protoporphyrin IX accumulates and is activated by light. The analog is more potent and longer-acting than native alpha-MSH because of amino-acid substitutions that resist enzymatic degradation. Additional antioxidant and anti-inflammatory melanocortin effects have been proposed but are less well characterized.
Mechanism pathways
Engaging melanocortin receptors, relevant to pigmentation, sexual arousal, and inflammation.
The melanocortin system consists of five G-protein-coupled receptors, MC1R through MC5R, and their natural ligands derived from proopiomelanocortin, including alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone. Each receptor subtype has a different distribution and a different job, which is why compounds acting on this family produce such varied effects depending on which receptors they touch. MC1R sits on epidermal melanocytes. Activating it raises cyclic AMP and shifts melanin synthesis toward eumelanin, the darker and more photoprotective pigment, independent of ultraviolet exposure. MC3R and MC4R are concentrated in the hypothalamus and limbic regions, where they participate in circuits governing appetite, energy balance, and sexual motivation. MC4R activation in particular is the accepted basis for centrally acting effects on arousal, which operate on motivation pathways rather than on vascular or genital tissue. MC5R is associated with exocrine gland function. Several melanocortin ligands also have anti-inflammatory activity, and this branch is pursued separately. Compounds in this group differ mainly by selectivity, and this is the distinction that determines both intended effect and side effect. A highly MC1R-selective analog is used to increase photoprotective pigmentation and is designed to avoid central receptors. Non-selective agonists bind across most of the family, which is why they produce pigmentation, appetite change, nausea, and arousal effects together rather than separately. A related tripeptide corresponding to the carboxy-terminal fragment of alpha-melanocyte-stimulating hormone retains anti-inflammatory activity but appears to work largely without classical melanocortin receptor engagement, entering cells through a peptide transporter instead. All of these analogs incorporate amino-acid substitutions that resist enzymatic breakdown, since the native hormones are short-lived. Clinical standing varies sharply within the group. Two members are approved medicines in at least some jurisdictions for narrowly defined indications, meaning their receptor mechanisms have been demonstrated in humans. Others in the group have never been approved anywhere and are sold as unregulated research chemicals. Non-selective melanocortin agonism in particular carries documented concerns including nausea, blood pressure effects, and changes to moles and pigmented lesions, and using pigmentation-inducing compounds without dermatological monitoring is widely cautioned against. Receptor pharmacology being well understood does not make an unapproved compound safe. The selectivity point is worth restating, because it is the single most useful thing to know about this family: the difference between a compound that touches one melanocortin receptor and one that touches all five is the difference between a narrow effect and a diffuse one.
The evidence
Approval rested on randomized, placebo-controlled trials in EPP. In the pivotal randomized controlled trial published in the New England Journal of Medicine (Langendonk, Balwani et al., 2015), patients receiving afamelanotide implants recorded more total hours of pain-free sunlight exposure than those on placebo across parallel European and U.S. studies. The FDA summary describes a European trial in which the afamelanotide group spent roughly 64 hours in direct midday sunlight on pain-free days versus about 41 hours for placebo over 180 days, with a second study of similar design over 270 days. Effect sizes were statistically significant but modest in absolute terms, and outcomes relied on patient-recorded diaries. Long-term extension and post-marketing data continue to track durability and safety. The design carries specific caveats. Both pivotal studies were sponsored by the manufacturer, enrolled small populations because EPP is a rare disease, and used a patient-reported diary of time in sunlight as the primary endpoint rather than an objective measurement of light exposure or an adjudicated clinical outcome. Blinding is difficult to maintain with an agent whose visible effect is skin darkening, so participants and investigators could often infer allocation, a recognized source of bias in subjective endpoints. Later work has tried to address the measurement problem directly by recording light exposure objectively in EPP patients (Molecular Genetics and Metabolism, 2022). Pharmacokinetic and pharmacodynamic characterization of the implant and its dermatologic uses has been reviewed separately (Clinical Pharmacokinetics, 2017). What the EPP approval establishes is narrow. It shows that a slow-release implant of a stable alpha-MSH analog, given under physician supervision to adults with a specific inherited photosensitivity disorder, increases self-reported pain-free daylight time versus placebo over months. It does not establish efficacy or safety for cosmetic tanning, for skin cancer prevention, for any other photosensitivity condition, or for self-administered injectable products. Evidence for the widely marketed tanning use of Melanotan I is not from these regulated trials and is not supported to the same standard. Melanotan II, a different and unapproved analog sold online, has never completed a comparable regulated program at all.
The evidence, in brief
An alpha-MSH analogue (historically Melanotan I) delivered as a physician-placed implant, and FDA-approved in 2019 as Scenesse. Approval rested on randomized placebo-controlled trials in erythropoietic protoporphyria showing more pain-free daylight hours than placebo, with modest absolute effect sizes based on patient diaries. The approved indication is photoprotection in a rare disease, not cosmetic tanning; unregulated Melanotan injectables sold online are a different, unapproved product.
- Langendonk JG, Balwani M et al.: Afamelanotide for Erythropoietic ProtoporphyriaN Engl J Med, 2015 (PMID 26132941)
- SCENESSE (afamelanotide) implant: FDA prescribing informationFDA / DailyMed
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #004
Approved or strong, consistent human evidence.
FDA-approved for a specific indication: the strongest lane.
Claim receipts
Popular claims about Afamelanotide, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
Randomized placebo-controlled trials in EPP supported approval of the implant in the EU and later the US.
The approval is a rare-disease photoprotection indication; cosmetic tanning was never the tested or authorized use.
Increased pigment does not equal cancer protection, and the labeling does not support a skin-cancer prevention claim.
Darkening of skin and existing moles is expected, which is why regular full-skin and mole monitoring accompanies supervised use.
The approved form is a physician-inserted implant made to pharmaceutical standards; online injectables have no verified content or sterility.
Safety profile
In EPP trials the most common adverse effects were implant-site reactions, headache, nausea, fatigue, and darkening of skin and pre-existing moles (expected from increased melanin). Because it drives pigmentation, regular full-skin and mole monitoring is advised, and the drug does not itself protect against UV-induced skin cancer. The trials that supported approval were small and ran for months rather than years, so long-term questions remain open: whether sustained melanocortin receptor stimulation influences melanocytic lesion behavior or melanoma risk over decades has not been resolved, which is one reason dermatologic surveillance is built into how the implant is used. Reviews of eruptive melanocytic nevi discuss the range of reported triggers, including drug exposures, and illustrate why new or changing pigmented lesions are treated as a monitoring priority in this setting. Unregulated Melanotan products sold online for tanning are a distinct safety concern: they are not the approved implant, may be contaminated or mis-dosed, and injectable use has been linked in case reports to nausea, blood-pressure changes, and changes in moles. These products bypass every control that applies to the licensed implant, which is manufactured to pharmaceutical standards, inserted by a trained physician, and dispensed only through certified prescribers under a specific rare-disease indication. Melanotan II in particular is an unapproved compound with no completed regulated trial program, sold with no verified content or sterility, and case reports describing adverse events after its use exist in the dermatology literature. This entry is educational and does not provide dosing guidance.
Compound notes
- Afamelanotide is a synthetic 13-amino-acid analog of alpha-melanocyte-stimulating hormone, historically studied under the research name Melanotan I.
- It is an MC1R agonist: activating melanocortin-1 receptors on epidermal melanocytes stimulates production of eumelanin, the darker and more photoprotective form of melanin, independent of ultraviolet exposure.
- Amino-acid substitutions make it more potent and longer-acting than native alpha-MSH by resisting enzymatic degradation.
- It is FDA-approved (2019, as Scenesse, with Orphan Drug and Priority Review designations) to increase pain-free light exposure in adults with erythropoietic protoporphyria, and is delivered as a physician-placed subcutaneous slow-release implant. The EMA authorized it in 2014.
Afamelanotide is the linear, MC1R-focused analog that completed Phase 3 and won approval for a photoprotection indication. Melanotan II is a separate cyclic, non-selective melanocortin agonist that was never approved and circulates as an unlicensed tanning product.
- Approved for photoprotection in erythropoietic protoporphyria, not for cosmetic tanning. The pivotal NEJM trial found a statistically significant but modest gain in pain-free daylight hours (about 64 versus 41 hours over 180 days in one study), from patient-recorded diaries.
- Common effects include implant-site reactions, headache, nausea, fatigue, and darkening of skin and pre-existing moles; regular full-skin and mole monitoring is advised, and the drug does not itself protect against UV-induced skin cancer.
- Unregulated Melanotan products sold online for tanning are not the approved implant and are a distinct safety concern.
Regulatory status
The FDA approved Scenesse (afamelanotide) in October 2019 to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria, with Orphan Drug and Priority Review designations; the European Medicines Agency had authorized it earlier (2014). It is a prescription implant administered by a trained physician. Melanotan-branded tanning products are not approved and are considered unapproved drugs in many jurisdictions.
Approved by the FDA for at least one indication.
By the numbers
- 01Synthetic alpha-MSH analog (Melanotan I); acts as an MC1R agonist to boost photoprotective eumelanin.
- 02FDA-approved in 2019 as Scenesse for erythropoietic protoporphyria (EPP), not for cosmetic tanning.
- 03Delivered as a subcutaneous slow-release implant roughly every two months by a physician.
- 04Pivotal NEJM RCT showed more pain-free daylight hours versus placebo (about 64 vs 41 hours over 180 days in one study).
- 05Received Orphan Drug and Priority Review status; also authorized in the EU since 2014.
- 06Online Melanotan injectables for tanning are unregulated and not the same as the approved implant.
Afamelanotide: research formats
Choose the format you are researching to see route-specific notes.
An implant, not an injection: a bioresorbable rod placed under the skin by a trained physician.
Afamelanotide is delivered as a slow-release bioresorbable implant, which is the single most important format fact about it. It is not drawn into a syringe and it is not self-administered. A trained physician places the implant subcutaneously, and it releases the alpha-MSH analog over time. The FDA approved Scenesse in October 2019 to increase pain-free light exposure in adults with erythropoietic protoporphyria, and the EMA authorized it in 2014.
Melanotan injectables sold online for tanning are not this product. They are unregulated, may be contaminated or mis-measured, and share only a receptor target with the approved implant.
The approved indication is photoprotection in a rare inherited condition, not cosmetic tanning. Reported adverse effects in the EPP trials included implant-site reactions, headache, nausea, fatigue, and darkening of skin and pre-existing moles.
Sources
Every factual claim above resolves to a real, published source.
- Afamelanotide for Erythropoietic ProtoporphyriaLangendonk JG, Balwani M, et al. N Engl J Med, 2015 (PMID 26132941)
- SCENESSE (afamelanotide) implant: FDA prescribing labelDailyMed, Clinuvel Inc. (EPP indication)
- PubMed: afamelanotide erythropoietic protoporphyriaPubMed literature search
- Pharmacokinetics and Pharmacodynamics of Afamelanotide and its Clinical Use in Treating Dermatologic DisordersClin Pharmacokinet, 2017 (PMID 28063031)
- Objective light exposure measurements and circadian rhythm in patients with erythropoietic protoporphyria: A case-control studyMol Genet Metab, 2022 (PMID 35034844)
- Eruptive Melanocytic Nevi: A ReviewAm J Clin Dermatol, 2019 (PMID 31119650); context on pigmented-lesion monitoring
- ClinicalTrials.gov: afamelanotide studiesRegistry search covering EPP and other investigated indications
Cite this page
PepCue. “Afamelanotide: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/afamelanotide.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.